Qlaira®: A 'natural' change of direction

Journal of Family Planning and Reproductive Health Care

Volumn 35, Issue 3, 2009, Pages 139-142

  Mansour, Diana ^a  

^a New Croft Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYPROTERONE ACETATE PLUS ESTRADIOL VALERATE; DESOGESTREL PLUS ETHINYLESTRADIOL; DIENOGEST; DIENOGEST PLUS ETHINYLESTRADIOL; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL PLUS LEVONORGESTREL; FEMILAR; LEVONORGESTREL; MESTRANOL; MINESSE; PLACEBO; QLAIRA; UNCLASSIFIED DRUG; CONTRACEPTIVE AGENT; ORAL CONTRACEPTIVE AGENT;

BLEEDING; CLINICAL TRIAL; DRUG COST; DRUG SAFETY; HUMAN; MENSTRUAL CYCLE; MENSTRUAL IRREGULARITY; NOTE; ORAL CONTRACEPTION; UNITED KINGDOM; ADOLESCENT; ADULT; ARTICLE; FEMALE; MIDDLE AGED; SEXUAL BEHAVIOR;

ADOLESCENT; ADULT; CONTRACEPTION BEHAVIOR; CONTRACEPTIVE AGENTS, FEMALE; CONTRACEPTIVES, ORAL; FEMALE; HUMANS; MIDDLE AGED; YOUNG ADULT;

EID: 67749114411     PISSN: 14711893     EISSN: None     Source Type: Journal    
DOI: 10.1783/147118909788707878     Document Type: Note

References (20)

1. van der Mooren MJ, Klipping C, van Aken B, Helmerhorst E, Spielmann D, Kluft C. A comparative study of the effects of gestodene 60 microg/ ethinylestradiol 15 microg and desogestrel 150 microg/ethinylestradiol 20 microg on hemostatic balance, blood lipid levels and carbohydrate metabolism. Eur J Contracept Reprod Health Care 1999; 4(Suppl. 2): 27-35.
2. Gestodene Study Group 322. The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestradiol 15 microg. Eur J Contracept Reprod Health Care 1999; 4(Suppl. 2): 9-15.
3. Hirvonen E, Stenman UH, Mälkönen M, Rasi V, Vartiainen E, Ylöstalo P. New natural oestradiol/cyproterone acetate oral contraceptive for pre-menopausal women. Maturitas 1988; 10: 201-213. (Pubitemid 18236700)
4. Kivinen S, Saure A. Efficacy and tolerability of a combined oral contraceptive containing 17 beta-estradiol and desogestrel. Eur J Contracept Reprod Health Care 1996; 1: 183.
5. National Agency for Medicines. Femilar tablets: Summary of Product Characteristics [in Finnish]. 14 May 2007. http://spc.nam.fi/indox/english/html/ nam/humspc/5/102855.shtml [Accessed 3 May 2009].
6. Oettel M, Carol W, Elger W, Kaufmann G, Moore C, Romer W, et al. A 19-norprogestin without 17β-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today 1995; 31: 517-536. (Pubitemid 26031142)
7. Sasagawa S, Shimizu Y, Nagaoka T, Tokado H, Imada K, Mizuguchi K. Dienogest, a selective progestin, reduces plasma estradiol level through induction of apoptosis of granulosa cells in the ovarian dominant follicle without follicle-stimulating hormone suppression in monkeys. J Endocrinol Invest 2008; 31: 636-641.
8. Rabe T, Kowald A, Ortmann J, Rehberger-Schneider S. Inhibition of skin 5 alpha-reductase by oral contraceptive progestins in vitro. Gynecol Endocrinol 2000; 14: 223-230. (Pubitemid 30783385)
9. Wiegratz I, Kutschera E, Lee JH, Moore C, Mellinger U, Winkler UH, et al. Effect of four different oral contraceptives on various sex hormones and serum-binding globulins. Contraception 2003; 67: 25-32. (Pubitemid 36084284)
10. Palombo-Kinne E, Schellschmidt I, Schumacher U, Gräser T. Efficacy of a combined oral contraceptive containing 0.030 mg ethinylestradiol/2 mg dienogest for the treatment of papulopustular acne in comparison with placebo and 0.035 mg ethinylestradiol/2 mg cyproterone acetate. Contraception 2009; 79: 282-289.
11. Hoffmann H, Moore C, Zimmermann H, Elger W, Schwarz S, Gräser T, et al. Approaches to the replacement of ethinylestradiol by natural 17beta-estradiol in combined oral contraceptives. Exp Toxicol Pathol 1998; 50: 458-464. (Pubitemid 28439499)
12. Endrikat J, Parke S, Trummer D, Schmidt W, Duijkers I, Klipping C. Ovulation inhibition with four variations of a four-phasic estradiol valerate/dienogest combined oral contraceptive: results of two prospective, randomized, open-label studies. Contraception 2008; 78: 218-225.
13. Coffee AL, Sulak PJ, Kuehl TJ. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen. Contraception 2007; 75: 444-449.
14. Lu M, Uddin A, Foegh M, Zeun S. Pharmacokinetics and pharmacodynamics of a new 4-phasic estradiol valerate and dienogest oral contraceptive. Poster presented at the American College of Obstetricians and Gynecologists 55th Annual Meeting, San Diego, CA, USA, May 2007.
15. Parke S, Nahum GG, Wildt L, Palacious S, Romer T, Bitzer J. Efficacy and tolerability of a new oral contraceptive containing estradiol and dienogest. Poster presented at the American College of Obstetricians and Gynecologists 56th Annual Meeting, New Orleans, LA, USA, May 2008.
16. Ahrendt H-J, Makalova D, Parke S, Mellinger U, Mansour D. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a 7-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinylestradiol/levonorgestrel. Contraception 2009; (in press).
17. Parke S, Nahum GG, Mellinger U, Junge W. Metabolic effects of a new 4-phasic combined oral contraceptive containing estradiol valerate and dienogest. Poster presented at the American College of Obstetricians and Gynecologists 56th Annual Meeting, New Orleans, LA, USA, May 2008.
18. Klipping C, Junge W, Mellinger U, Duijkers I, Parke S. Hemostatic effects of a novel four-phasic combined oral contraceptive containing estradiol valerate and dienogest. Poster presented at the European Society of Contraception Biannual Meeting, Prague, Czechoslovakia, April 2008.
19. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect of different progestogens in low oestrogen oral contraceptives on venous thromboembolic disease. Lancet 1995; 346: 1582-1588.
20. Bayer pic. Qlaira: Summary of Product Characteristics. http://emc.medicines.org.uk/document.aspx?documentId=21700 [Accessed 3 May 2009].